{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:29:51Z","timestamp":1725280191774},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/md.0000000000002355","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T06:57:36Z","timestamp":1450853856000},"page":"e2355","source":"Crossref","is-referenced-by-count":4,"title":["Fixed-Dose Combinations of Renin\u2013Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension"],"prefix":"10.1097","volume":"94","author":[{"given":"Fu-Chih","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chang","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shing-Hsien","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Pin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pao-Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-37-20210226","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(14)62256-X","article-title":"A public health approach to global management of hypertension","volume":"385","author":"Angell","year":"2015","journal-title":"Lancet"},{"key":"R2-37-20210226","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.1996.03530440051036","article-title":"Blood pressure as a cardiovascular risk factor: prevention and treatment","volume":"275","author":"Kannel","year":"1996","journal-title":"JAMA"},{"key":"R3-37-20210226","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bmj.322.7294.1107","article-title":"What are the elements of good treatment for hypertension?","volume":"322","author":"Mulrow","year":"2001","journal-title":"BMJ"},{"key":"R4-37-20210226","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jama.2013.184182","article-title":"Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries","volume":"310","author":"Chow","year":"2013","journal-title":"JAMA"},{"key":"R5-37-20210226","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jacc.2012.04.026","article-title":"Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010","volume":"60","author":"Guo","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R6-37-20210226","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/HJH.0b013e3282f3b352","article-title":"Evidence for improved control of hypertension in Taiwan: 1993\u20132002","volume":"26","author":"Su","year":"2008","journal-title":"J Hypertens"},{"key":"R7-37-20210226","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"R8-37-20210226","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2014.868629","article-title":"2013 ESH\/ESC Practice Guidelines for the Management of Arterial Hypertension","volume":"23","author":"Mancia","year":"2014","journal-title":"Blood Press"},{"key":"R9-37-20210226","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2015.02.038","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension","volume":"65","author":"Rosendorff","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R10-37-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcma.2014.11.005","article-title":"2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension","volume":"78","author":"Chiang","year":"2015","journal-title":"J Chin Med Assoc"},{"key":"R11-37-20210226","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jash.2010.03.001","article-title":"Combination therapy in hypertension","volume":"4","author":"Gradman","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"R12-37-20210226","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1751-7176.2009.00138.x","article-title":"Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy","volume":"11","author":"Elliott","year":"2009","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R13-37-20210226","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","article-title":"Initial monotherapy and combination therapy and hypertension control the first year","volume":"59","author":"Egan","year":"2012","journal-title":"Hypertension"},{"key":"R14-37-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jch.12449","article-title":"Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine\/valsartan","volume":"17","author":"Tung","year":"2015","journal-title":"J Clin Hypertens (Greenwich"},{"key":"R15-37-20210226","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"R16-37-20210226","first-page":"141","article-title":"High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese","volume":"40","author":"Woo","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R17-37-20210226","doi-asserted-by":"crossref","first-page":"146","DOI":"10.11622\/smedj.2014034","article-title":"Incidence of discontinuation of angiotensin-converting enzyme inhibitors due to cough, in a primary healthcare centre in Singapore","volume":"55","author":"Ng","year":"2014","journal-title":"Singapore Med J"},{"key":"R18-37-20210226","first-page":"49","article-title":"Secular trends in prescription patterns of single-pill combinations of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker plus a thiazide diuretic for hypertensive patients in Taiwan","volume":"29","author":"Hsu","year":"2013","journal-title":"Acta Cardiol Sin"},{"key":"R19-37-20210226","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.jhh.1002316","article-title":"Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study","volume":"22","author":"Boyko","year":"2008","journal-title":"J Hum Hypertens"},{"key":"R20-37-20210226","first-page":"387","article-title":"Five-year outcomes after acute myocardial infarction in patients with and without diabetes mellitus in Taiwan, 1996\u20132005","volume":"29","author":"Chiang","year":"2013","journal-title":"Acta Cardiol Sin"},{"key":"R21-37-20210226","doi-asserted-by":"crossref","first-page":"e0130807","DOI":"10.1371\/journal.pone.0130807","article-title":"Major adverse cardiovascular events in treated periodontitis: a population-based follow-up study from Taiwan","volume":"10","author":"Chou","year":"2015","journal-title":"PloS One"},{"key":"R22-37-20210226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2261-14-38","article-title":"Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan","volume":"14","author":"Lin","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"R23-37-20210226","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.amjcard.2010.08.073","article-title":"Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan","volume":"107","author":"Lin","year":"2011","journal-title":"Am J Cardiol"},{"key":"R24-37-20210226","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/STROKEAHA.108.540880","article-title":"Preeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan","volume":"40","author":"Tang","year":"2009","journal-title":"Stroke"},{"key":"R25-37-20210226","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MAJ.0b013e318278707f","article-title":"Major adverse cardiovascular events and mortality in systemic lupus erythematosus patients after successful delivery: a population-based study","volume":"347","author":"Wu","year":"2014","journal-title":"Am J Med Sci"},{"key":"R26-37-20210226","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"R27-37-20210226","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","article-title":"Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention","volume":"115","author":"Rosendorff","year":"2007","journal-title":"Circulation"},{"key":"R28-37-20210226","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"R29-37-20210226","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"R30-37-20210226","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/erc.13.42","article-title":"The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review","volume":"11","author":"Ferrari","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R31-37-20210226","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R32-37-20210226","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"R33-37-20210226","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"R34-37-20210226","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R35-37-20210226","doi-asserted-by":"crossref","first-page":"10A","DOI":"10.1016\/j.amjcard.2009.10.006","article-title":"Progression of cardiovascular damage: the role of renin-angiotensin system blockade","volume":"105","author":"Probstfield","year":"2010","journal-title":"Am J Cardiol"},{"key":"R36-37-20210226","doi-asserted-by":"crossref","first-page":"693","DOI":"10.7326\/0003-4819-141-9-200411020-00011","article-title":"Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction","volume":"141","author":"Lee","year":"2004","journal-title":"Ann Intern Med"},{"key":"R37-37-20210226","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","article-title":"Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"57","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"R38-37-20210226","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourciere","year":"2000","journal-title":"Kidney Int"},{"key":"R39-37-20210226","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"R40-37-20210226","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R41-37-20210226","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar","year":"2008","journal-title":"Ann Intern Med"},{"key":"R42-37-20210226","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R43-37-20210226","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R44-37-20210226","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/VHRM.S17168","article-title":"Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials","volume":"7","author":"Baumhakel","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R45-37-20210226","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/HYPERTENSIONAHA.113.02382","article-title":"Adrenal signaling in heart failure something more than a distant ship's smoke on the horizon","volume":"63","author":"Santulli","year":"2014","journal-title":"Hypertension"},{"key":"R46-37-20210226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphys.2013.00209","article-title":"Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the beta adrenergic system","volume":"4","author":"Santulli","year":"2013","journal-title":"Front Physiol"},{"key":"R47-37-20210226","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1016\/j.jacc.2014.09.070","article-title":"Different potencies of angiotensin receptor blockers at suppressing adrenal beta-Arrestin1-dependent post-myocardial infarction hyperaldosteronism","volume":"64","author":"Lymperopoulos","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R48-37-20210226","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1038\/srep08116","article-title":"Suppression of adrenal betaarrestin1-dependent aldosterone production by ARBs: head-to-head comparison","volume":"5","author":"Dabul","year":"2015","journal-title":"Sci Rep"},{"key":"R49-37-20210226","first-page":"7","article-title":"A promising choice in hypertension treatment: fixed-dose combinations","volume":"9","author":"Wan","year":"2014","journal-title":"Asian J Pharm Sci"},{"key":"R50-37-20210226","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00129784-200808010-00006","article-title":"Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine\/benazepril versus component-based free-combination therapy","volume":"8","author":"Dickson","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"R51-37-20210226","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ncpcardio1419","article-title":"Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population","volume":"6","author":"Sanz","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R52-37-20210226","first-page":"967073","article-title":"The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis","volume":"2014","author":"van Galen","year":"2014","journal-title":"AIDS Res Treat"},{"key":"R53-37-20210226","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"R54-37-20210226","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/HYPERTENSIONAHA.113.02382","article-title":"Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon","volume":"63","author":"Santulli","year":"2014","journal-title":"Hypertension"},{"key":"R55-37-20210226","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphys.2013.00209","article-title":"Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the beta adrenergic system","volume":"4","author":"Santulli","year":"2013","journal-title":"Front Physiol"},{"key":"R56-37-20210226","first-page":"2059","article-title":"Indication and advantage of combination therapy with angiotensin II receptor blocker (ARB) and calcium channel antagonist","volume":"69","author":"Yamaguchi","year":"2011","journal-title":"Nihon Rinsho"},{"key":"R57-37-20210226","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.clinthera.2012.07.001","article-title":"I-ADD study: assessment of efficacy and safety profile of irbesartan\/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150\u200amg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study","volume":"34","author":"Bobrie","year":"2012","journal-title":"Clin Ther"},{"key":"R58-37-20210226","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.clinthera.2012.06.026","article-title":"I-COMBINE study: assessment of efficacy and safety profile of irbesartan\/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5\u200amg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study","volume":"34","author":"Bobrie","year":"2012","journal-title":"Clin Ther"},{"key":"R59-37-20210226","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/HJH.0b013e328013cd67","article-title":"The Pl(A1\/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients","volume":"25","author":"Lanni","year":"2007","journal-title":"J Hypertens"},{"key":"R60-37-20210226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2261-10-41","article-title":"The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events","volume":"10","author":"Galasso","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"R61-37-20210226","doi-asserted-by":"crossref","first-page":"e001081","DOI":"10.1161\/JAHA.112.001081","article-title":"CaMK4 gene deletion induces hypertension","volume":"1","author":"Santulli","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"R62-37-20210226","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40292-013-0001-8","article-title":"G-protein-coupled receptor kinase 2 and hypertension: molecular insights and pathophysiological mechanisms","volume":"20","author":"Santulli","year":"2013","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:56:59Z","timestamp":1620961019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201512210-00037"}},"subtitle":["A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":62,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002355","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}